Effect of interventional embolotherapy on FHIT and p16 expression in hepatocellular carcinoma patients

Xu,Wei; Qi,Xiaogai; Wang,Xia; Sun,Jize

doi:10.3892/ol.2018.9648

Effect of interventional embolotherapy on FHIT and p16 expression in hepatocellular carcinoma patients

Authors:
- Wei Xu
- Xiaogai Qi
- Xia Wang
- Jize Sun
View Affiliations

Affiliations: Department of Intervention, Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong 266042, P.R. China, Department of Radiotherapy, Qingdao Cancer Hospital, Qingdao, Shandong 266042, P.R. China, Department of Ultrasound, Qingdao Cancer Hospital, Qingdao, Shandong 266042, P.R. China
Published online on: October 31, 2018 https://doi.org/10.3892/ol.2018.9648
Pages: 871-876
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effects of interventional embolotherapy on the expression of fragile histidine triad (FHIT) and p16 in hepatocellular carcinoma (HCC) patients were investigated. Patients with primary HCC who were definitely diagnosed and treated in the Department of Gastroenterology in Qingdao Central Hospital from March 2014 to March 2016 were selected, and they underwent interventional embolotherapy. HCC and cancer‑adjacent tissues of the patients were harvested for immunohistochemical staining. The correlation between the expression levels of FHIT and p16 was analyzed at the gene and protein level. Clinical data were collected, and whether they were correlated with the expression of FHIT and p16 was investigated. The expression levels of FHIT and p16 in primary HCC tissues were remarkably lower than that in cancer‑adjacent tissues (P<0.05). In HCC tissues, FHIT expression was obviously positively correlated with p16 expression (Spearman's correlation coefficient, r=0.308; P=0.025). FHIT was related to HCC tumor‑node‑metastasis (TNM) staging, the differentiation degree in Edmondson‑Steiner grading, lymph node metastasis and portal vein thrombosis (P<0.05 in all comparisons), whereas, p16 was associated with tumor size and the differentiation degree in Edmondson‑Steiner grading (P<0.05 in all comparisons). The expression of FHIT and p16 genes and proteins in HCC tissues were obviously lower than those in cancer‑adjacent tissues (P<0.05 in all comparisons). FHIT and p16 genes, as tumor suppressor genes, inhibit the proliferation of HCC, and there is a positive correlation between them. The proteins of the FHIT and p16 can be used as new indicators for clinical detection, thus providing a new method for clinical diagnosis.

View Figures

View References

1	Rasheed MA, Tariq F, Afzal S and Mannanv S: In silico analysis of fragile histidine triad involved in regression of carcinoma. J Pak Med Assoc. 67:616–621. 2017.PubMed/NCBI
2	Sun G, Zhang C, Feng M, Liu W, Xie H, Qin Q, Zhao E and Wan L: Methylation analysis of p16, SLIT2, SCARA5, and Runx3 genes in hepatocellular carcinoma. Medicine (Baltimore). 96:e82792017. View Article : Google Scholar : PubMed/NCBI
3	Zekri AR, Bahnasy AA, Shoeab FE, Mohamed WS, El-Dahshan DH, Ali FT, Sabry GM, Dasgupta N and Daoud SS: Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma. J Adv Res. 5:27–40. 2014. View Article : Google Scholar : PubMed/NCBI
4	Cai JP, Wang YD, Zhang X and Xue HZ: Expression of P16 and survivin in liver cancer and their clinical significance. Zhonghua Gan Zang Bing Za Zhi. 25:778–780. 2017.(In Chinese). PubMed/NCBI
5	Zhang C, Ye L, Guan S, Jin S, Wang W, Sun S, Lee KH, Wei J and Liu B: Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer. Tumour Biol. 35:2047–2051. 2014. View Article : Google Scholar : PubMed/NCBI
6	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
7	Zaki SM, Abdel-Azeez HA, El Nagar MR, Metwally KA and S Ahmed MM: Analysis of FHIT gene methylation in egyptian breast cancer women: Association with clinicopathological features. Asian Pac J Cancer Prev. 16:1235–1239. 2015. View Article : Google Scholar : PubMed/NCBI
8	Lassen P, Primdahl H, Johansen J, Kristensen CA, Andersen E, Andersen LJ, Evensen JF, Eriksen JG and Overgaard J; Danish Head and Neck Cancer Group (DAHANCA), . Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer. Radiother Oncol. 113:310–316. 2014. View Article : Google Scholar : PubMed/NCBI
9	Shu R, He J, Wu C and Gao J: The association between RARβ and FHIT promoter methylation and the carcinogenesis of patients with cervical carcinoma: A meta-analysis. Tumour Biol. 39:10104283177091262017. View Article : Google Scholar : PubMed/NCBI
10	Yu GR, Qin WW, Li JP, Hua W, Meng YL, Chen R, Yan B, Wang L, Zhang X, Jia LT, et al: HIV-TAT-fused FHIT protein functions as a potential pro-apoptotic molecule in hepatocellular carcinoma cells. Biosci Rep. 32:271–279. 2012. View Article : Google Scholar : PubMed/NCBI
11	Fassan M, Rusev B, Corbo V, Gasparini P, Luchini C, Vicentini C, Mafficini A, Paiella S, Salvia R, Cataldo I, et al: Fhit down-regulation is an early event in pancreatic carcinogenesis. Virchows Arch. 470:647–653. 2017. View Article : Google Scholar : PubMed/NCBI
12	Lim HK, Park JM, Chi KC, Lee EJ and Jeong EM: Disappearance of serum methylated p16 indicates longer survival in patients with gastric cancer. J Gastric Cancer. 13:157–163. 2013. View Article : Google Scholar : PubMed/NCBI
13	Czarnecka KH, Migdalska-Sęk M, Domańska D, Pastuszak-Lewandoska D, Dutkowska A, Kordiak J, Nawrot E, Kiszałkiewicz J, Antczak A and Brzeziańska-Lasota E: FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer. Int J Oncol. 49:1175–1184. 2016. View Article : Google Scholar : PubMed/NCBI
14	Shan M, Zhang X, Liu X, Qin Y, Liu T, Liu Y, Wang J, Zhong Z, Zhang Y, Geng J, et al: p16 and p53 play distinct roles in different subtypes of breast cancer. PLoS One. 8:e764082013. View Article : Google Scholar : PubMed/NCBI
15	Tamoto A, Yashima K, Hosoda K, Yamamoto S, Kawata S, Ikebuchi Y, Matsumoto K, Kawaguchi K, Harada K, Murawaki Y, et al: Protein expression of fragile histidine triad and cyclooxgenase-2 in serrated neoplasia of the colorectum. Oncol Lett. 14:3683–3688. 2017. View Article : Google Scholar : PubMed/NCBI
16	Zhang JX, Han YP, Bai C and Li Q: Notch1/3 and p53/p21 are a potential therapeutic target for APS-induced apoptosis in non-small cell lung carcinoma cell lines. Int J Clin Exp Med. 8:12539–12547. 2015.PubMed/NCBI
17	Lv X, Ye G, Zhang X and Huang T: p16 Methylation was associated with the development, age, hepatic viruses infection of hepatocellular carcinoma, and p16 expression had a poor survival: A systematic meta-analysis (PRISMA). Medicine (Baltimore). 96:e81062017. View Article : Google Scholar : PubMed/NCBI
18	Kumar R, Ghosh SK, Verma AK, Talukdar A, Deka MK, Wagh M, Bahar HM, Tapkire R, Chakraborty KP and Kannan RR: p16 expression as a surrogate marker for HPV infection in esophageal squamous cell carcinoma can predict response to neo-adjuvant chemotherapy. Asian Pac J Cancer Prev. 16:7161–7165. 2015. View Article : Google Scholar : PubMed/NCBI
19	Seiwert TY: Ties that bind: p16 as a prognostic biomarker and the need for high-accuracy human papillomavirus testing. J Clin Oncol. 32:3914–3916. 2014. View Article : Google Scholar : PubMed/NCBI
20	Wu X, Wu G, Yao X, Hou G and Jiang F: The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: A meta-analysis and literature review. Drug Des Devel Ther. 10:699–709. 2016.PubMed/NCBI
21	Mai S, Welzel G, Ottstadt M, Lohr F, Severa S, Prigge ES, Wentzensen N, Trunk MJ, Wenz F, von Knebel-Doeberitz M, et al: Prognostic relevance of HPV infection and p16 overexpression in squamous cell anal cancer. Int J Radiat Oncol Biol Phys. 93:819–827. 2015. View Article : Google Scholar : PubMed/NCBI